Lung cancer pilot study begins
August 20, 2012
Does providing evidence-based medicine 100 percent of the time make a noted and consistent difference in patient outcomes? Providence believes so, and strives for that. And now Providence is helping to prove it.
Beginning this month, Providence Portland Medical Center starts a national pilot study that promotes evidence-based evaluation and treatment standards for patients with resectable non-small cell lung cancer. Providence Portland is one of 12 sites participating in the American College of Surgeon’s Commission on Cancer National Pilot II Study for the ProvenCare Lung Cancer Collaborative. The study is based on the success of the Geisinger Health System’s ProvenCare model.
At Providence Portland, multidisciplinary treatment teams have committed to providing 38 established care steps to ensure non-small cell lung cancer patients receive the highest standard of care. As importantly, patients in the study commit to communicate with their surgical teams and get their families involved in the treatment plan. Research studies show that patients have better results when they participate in their medical care. Participation in the Phase II study began Aug. 6. The goal is to add 500 patients, nationally, in this phase of the study.
Providence was invited to join the collaborative due to the work of the multidisciplinary team members who care for thoracic patients and in particular, John Handy Jr., M.D., Hon.D., medical director, Providence Thoracic Surgery Program, co-medical director, Providence Thoracic Oncology Program, and lead surgeon with the Providence Thoracic Surgery Initiative.